FierceBiotech· @FierceBiotech · X·· 4 天前精选AI 评分58
AI 导读
Cellectis 计划到2027年裁减至多70%的员工,并逐步退出同种异体 CAR-T 疗法,转而聚焦体内基因编辑。该生物技术公司未在材料中披露裁员的具体人数或成本节省规模。
推荐理由
Cellectis 到2027年最多裁减70%员工并转向体内基因编辑,读者可据此观察细胞治疗企业的战略收缩。
正文
Cellectis plans to cut up to 70% of its workforce through 2027 as the biotech shifts away from allogeneic CAR-T therapies to focus on in vivo gene editing. https://www.fiercebiotech.com/biotech/cellectis-will-shed-70-workforce-part-vivo-pivot
来源:FierceBiotech · x.com